Latest News

Many investors are asking whether Lockheed Martin is still attractive at around $465 a share, or if most of the potential upside has already been reflected in the price. This breakdown examines that question in detail. The stock has risen about 6% over the last week and 1.5% over the past month, but it is still down 3.5% year to date and roughly 6.1% over the last year. In that context, its 49.3% gain over five years may appear somewhat underappreciated. Recent headlines have highlighted...

Southern Palladium Limited ( ASX:SPD ) insiders who purchased shares in the last 12 months were richly rewarded last...

Rio Tinto Group (LSE:RIO) has quietly added momentum recently, with the share price up about 1% in a day, 2% over the week, and roughly 6% this month, inviting a closer look. See our latest analysis for Rio Tinto Group. That recent 1 month share price return of 5.78% builds on a strong 90 day share price gain of 20.58%, while the 1 year total shareholder return of 15.04% signals steady, not explosive, momentum for Rio Tinto at its current £55.28 level. If Rio Tinto’s move has you thinking...

Danone (ENXTPA:BN) has quietly slipped about 3 % over the past month, even as its year to date gain sits near 17 %, prompting a fresh look at whether the current pullback offers value. See our latest analysis for Danone. That recent 3 % slide caps a softer 30 day share price return of around minus 3 %, but it comes after a solid year to date share price gain and strong multi year total shareholder returns. This suggests momentum is pausing rather than breaking. If Danone’s quieter pullback...

IonQ (IONQ) just checked two big boxes at once, rolling out Slovakia’s first national quantum communication network while also teaming up with a leading regenerative medicine group on quantum AI powered drug development. See our latest analysis for IonQ. All of this comes as IonQ’s share price has climbed to about $54.36, with a 7 day share price return of 15.37% and a 1 year total shareholder return of 58.76%. This suggests momentum is rebuilding after recent volatility and is still grounded...

Caleres (CAL) opened Q3 2026 with total revenue of about $790 million and EPS of $0.07, while trailing twelve month revenue stood at roughly $2.7 billion with EPS of $0.52, setting a cautious tone around profitability. The company has seen revenue move from $741 million and EPS of $1.20 in Q3 2025 to $790 million and EPS of $0.07 in Q3 2026, a shift that leaves investors watching how much of the story is about topline resilience versus pressure further down the income statement. With net...

Key Insights Gakujo's significant individual investors ownership suggests that the key decisions are influenced by...

In recent days, Apogee Therapeutics reported positive interim Phase 1 results for its lead antibody APG333, showing a roughly 55-day half-life and biomarker suppression lasting up to six months, while also closing a public offering that raised about US$345,000,000 in gross proceeds. These updates, reinforced by multiple optimistic analyst views and insider stock sales executed under pre-arranged Rule 10b5-1 plans, spotlight a company pairing a potentially convenient dosing profile with a...

In early December 2025, Swiss Re AG set net income targets of more than US$4.40 billion for 2025 and US$4.50 billion for 2026, alongside confirming plans for a conditional share buyback program and ongoing business portfolio reviews. Investors are scrutinizing how these profit goals, seen as below prior market hopes, and the planned but modest share repurchases balance against Swiss Re’s AI-led transformation and cost-efficiency ambitions. We’ll now examine how Swiss Re’s below-expectation...

Designer Brands (DBI) has just posted its Q3 2026 numbers, logging revenue of $752 million and basic EPS of $0.35 as net income reached $18.2 million. The company has seen revenue move from $771.9 million in Q2 2025 to $777.2 million in Q3 2025 and then to $752 million in the latest quarter, while EPS has swung from $0.24 in Q2 2025 to $0.25 in Q3 2025 and now $0.35. This sets up a narrative where higher profitability in the latest quarter sits against a still choppy top line. Overall,...

From what we can see, insiders were net sellers in China XLX Fertiliser Ltd.'s ( HKG:1866 ) during the past 12 months...

Wondering if Charter Communications at around $204 a share is a value trap or a rare bargain hiding in plain sight? You are not the only one looking at this beaten up cable giant and asking if the downside has already been priced in. Despite a rough longer term track record, with the stock down about 41.4% year to date and 44.1% over the last year, it has shown some short term life, gaining roughly 3.9% in the last week after a 6.9% slide over the past month. Recent moves have been driven...

If you are wondering whether Coterra Energy is still a smart buy at around $26.86, you are not alone, and the numbers behind its valuation are more interesting than the headline price suggests. The stock has inched up 1.8% over the last week and 1.1% over the last month, and those modest near term moves sit on top of a 12.1% 1 year gain and a 100.9% rise over 5 years. Recent news flow around disciplined capital allocation, including continued focus on returning cash to shareholders through...

Manhattan Associates (MANH) has quietly slid over the past year, with the stock down about 41% from its peak even as revenue and net income keep growing at a steady, mid single digit clip. See our latest analysis for Manhattan Associates. That slide has been driven less by a single headline and more by a reset in expectations, with a roughly 16.7% 90 day share price decline and a far steeper 40.6% one year total shareholder return drop contrasting with still healthy multi year total...

Cousins Properties recently received an upgrade to a Zacks Rank #2 (Buy), after analysts steadily raised their earnings estimates over recent months. This shift in analyst sentiment points to improving expectations for the REIT’s underlying business performance and earnings outlook. Next, we’ll explore how the Zacks rating upgrade and rising earnings estimates may reshape Cousins Properties’ broader investment narrative. Outshine the giants: these 27 early-stage AI stocks could fund your...

We feel now is a pretty good time to analyse Money Forward, Inc.'s ( TSE:3994 ) business as it appears the company may...

Fourth Quarter Beat and Insider Buying Put Blue Bird in Focus Blue Bird (BLBD) just delivered a stronger than expected fiscal fourth quarter, with earnings and revenue topping forecasts, followed quickly by an insider share purchase that underscores management’s confidence. See our latest analysis for Blue Bird. The upbeat quarter and insider buying come after a choppy few months, with a roughly flat 1 month share price return. However, the year to date share price return of about 31 percent...

Wondering whether Textron is still a smart buy at today’s price, or if most of the upside is already baked in? This breakdown will help you decide with a cool head. The stock has quietly climbed 1.8% over the last week and 2.3% over the past month, adding to a 10.7% gain year to date and a strong 75.5% over five years, which naturally raises the question of how much value is left on the table. Recent news has focused on Textron’s growing defense and aviation footprint, from expanding...

If you are wondering whether CVS Health is still a bargain after its big comeback, you are not alone. This stock has quietly turned into one of the more interesting value stories in healthcare. After a choppy few years, CVS is up 76.9% year to date and 47.9% over the last 12 months, even though the last month was slightly negative at -0.9% and the last week only inched ahead by 0.8%. Part of this renewed interest comes from CVS leaning harder into its integrated healthcare model, combining...

The last three months have been tough on PharmaResearch Co., Ltd. ( KOSDAQ:214450 ) shareholders, who have seen the...

If you are wondering whether F5 at around $257 a share is still worth considering after its big run, or if you have missed the boat, this is a good place to unpack what the current price implies. Over the last week the stock is up 8.2%, adding to a 5.0% gain over 30 days and a 66.9% rise over three years, even though the 1 year return is only 0.9% and the move year to date is 2.5%. That uneven performance has played out alongside a steady sequence of product and strategy updates, from F5...

Lumen Technologies (LUMN) just gave investors a lot to digest, pairing a fresh cybersecurity launch for AWS customers with a pending handoff in its top technology role. Both moves point straight at its cloud security ambitions. See our latest analysis for Lumen Technologies. The leadership shuffle and new AWS security product land as Lumen’s share price sits at $8.37, with a punchy 90 day share price return of 48.67 percent and a 3 year total shareholder return of 50.54 percent, suggesting...

If you are wondering whether Flex is still attractive after such a huge run, or if you may be late to the party, this breakdown will help you assess whether the current price still makes sense. The stock has surged 17.6% over the last week, is up 7.8% in the past month, and has risen 74.9% year to date, with a 78.1% gain over the last year and 301.1% over three years, which has clearly changed how the market views its potential. Recently, investors have been reacting to Flex’s role in...

Wondering if Snowflake is still worth buying after its run up and recent wobble, or if the smart money has already moved on? You are not alone, and that is exactly what we are going to unpack here. Despite a strong longer term picture with the stock up 43.0% year to date and 31.3% over the last year, the recent pullback of 13.2% over 7 days and 14.3% over 30 days has reset expectations and opened up fresh questions about risk and reward. Those swings have come as investors digest a wave of...